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BRIEF CLINICAL REPORTSSurgical excision of right ventricular carcinoid tumor
in a symptomatic patient without carcinoid valve diseaseBasar Sareyyupoglu, MD,a Heidi M. Connolly, MD,b and Hartzell V. Schaff, MD,a Rochester, MinnThis report describes the unusual presentation of a 55-year-
old man with normal cardiac valves who had metastatic car-
cinoid tumor in the heart. The patient underwent coronary
artery bypass grafting at another hospital in 1982. In 2004
he had partial colectomy for tumor removal, and pathologic
examination disclosed carcinoid cell type. Hepatic metasta-
ses were treated with arterial embolization. At the time of
evaluation at the Mayo Clinic, he did not report diarrhea
but had noticed increasing frequency of facial flushing; he
had started taking somatostatin 4 months earlier. A com-
puted tomography scan in March of 2008 demonstrated
a tumor in the mediastinum, and this was a new finding com-
pared with a similar study in September 2005. The 4- to
5-cm mass compressed the right ventricle (Figure 1, A, B).
In addition to worsening flushing, he had symptoms of pre-
syncope, shortness of breath, and limited exercise capacity.
His echocardiogram showed no evidence of valvular dis-
ease, and his left ventricular function was normal.CLINICAL SUMMARY
The patient was advised to undergo excision of the right
ventricular tumor. After a repeat median sternotomy was
made, the left-sided saphenous vein was identified and pre-
served. There was a 3.53 4.5-cm tumor in the free wall of the
right ventricle. A thin layer of muscle and fat covered the tu-
mor (Figure 2, A), and the mass projected into the ventricle
over a small area. Cardiopulmonary bypass was initiated by
using an inflow arterial cannula in the ascending aorta and
an outflow single 2-stage venous cannula in the right atrium.
The heart was allowed to beat rhythmically while the tumor
was removed; we dissected over the tumor in the right ventri-
cle,making an oblique incision in the line of themuscle fibers.
Most of the tumor was within the right ventricular muscle, and
there was a capsule around the tumor (Figure 2, B), which was
removed completely by using a combination of sharp and
blunt dissection (Figure 2, C, D). Removal of the massFIGURE 1. A, Computed tomography in patient taken in horizontal long
axis derivation and (B) magnetic resonance angiography cine taken in
lateral short axis derivation showing tumor (arrows) compressing right
ventricular outflow tract.
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FIGURE 2. Operative excision of the carcinoid tumor. A, Tumor covered with thin epicardial fat and muscle projecting on the right venricle. B, Capsulated
tumor within the ventricle. C, Removal of the tumor resulted in a 2-cm diameter communication with the right ventricular cavity; Swan catheter is seen through
the communication. D, Gross appearance of the resected tumor. E, Primary closure of the epicardial layer.
Brief Clinical Reportsresulted in a 2-cm diameter communication with the right
ventricular cavity (Figure 2, C); this was closed with 2 pledg-
eted 3-0 Prolene sutures. The remainder of the bed of the tu-
mor within the right ventricular muscle was obliterated with
interrupted 3-0 Prolene sutures, and the epicardial layer was
closed in 2 layers with 3-0 Prolene sutures (Figure 2, E).
The patient’s recovery was uncomplicated, and a follow-
up computed tomography scan 1 year postoperatively
showed no recurrence or additional metastases. Fifteen
months postoperatively, the patient is still receiving octreo-
tide and reports no symptoms.
DISCUSSION
Breast, lung, and malignant melanomas are the most com-
mon primary tumors that metastasize the heart.1 Carcinoid tu-
mors are rare, arising in 1.2 to 2.1 per 100,000 persons in the
general population per year.2 Flushing, gastrointestinal hyper-
motility (secretory diarrhea), bronchospasm, and carcinoid
heart disease are the common presentations of the malignant
carcinoid syndrome. The diagnosis of carcinoid syndrome is
usually suspected by clinical features and confirmed by in-
creased levels of the by-product of serotoninmetabolism, 5-hy-
droxyindoleacetic acid. Right-sided valvular dysfunction is the
pathognomonic feature of carcinoid heart disease. There has
been only 1 series reporting the clinical and tumor characteris-
tics along with echocardiographic and pathologic features of
metastatic carcinoid to the heart.3 Of the 243 patients seen
with carcinoid heart disease from 1985 to 1999 at the Mayo
Clinic, 11 (4%) were identified as having metastatic carcinoid
tumor involving the heart, and among those, only 6 underwent
surgical excision of the tumor; in the remaining 5 patients,e24 The Journal of Thoracic and Cardiovascular Surgdiagnosis was made at autopsy.3 On echocardiographic evalu-
ation, metastatic carcinoid tumor appears as a homogeneous,
circumscribed, noninfiltrating mass affecting the left or right
ventricular myocardium. Although metastatic carcinoid tumor
is uncommon, it has echocardiographic characteristics that
make it easily identifiable when it is 1.0 cm or larger.
In a study with 100 consecutive patients who underwent
cardiac surgery for carcinoid disease, Weingarten and asso-
ciates4 emphasized that hypotension in patients with carci-
noid heart disease should be treated with octreotide, but
vasoactive medications can be safely administered for re-
fractory hypotension in the presence of octreotide. Although
our patient had received his monthly long-acting dose of oc-
treotide treatment, during the operation and on manipulation
of the mass on cardiopulmonary bypass, additional doses of
octreotide up to 4000 mg were needed for hemodynamic sup-
port and brief periods of hypotension.CONCLUSIONS
Metastatic carcinoid tumor may be the only manifestation
of carcinoid heart disease. The comprehensive echocardio-
graphic assessment of a patient with carcinoid disease should
include a search for carcinoidmetastases, even in the absence
of carcinoid valvular disease.3 As demonstrated by our pa-
tient, metastatic carcinoid disease in the myocardium may
cause symptoms that are ameliorated by tumor removal.References
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1192-9.Use of a hybrid operating room to diagnose and treat delayed
coronary spasm after mitral valve repairJared L. Antevil, MD, Alexandros N. Karavas, MD, John H. Selby, MD, and John G. Byrne, MD,
Nashville, TennWedescribe a case of delayed circulatory collapse after mitral
valve repair caused by diffuse coronary artery vasospasm.
The cause and management of this condition are discussed.
CLINICAL SUMMARY
A 66-year-old woman presented with severe symptomatic
mitral valve regurgitation. Although cardiac catheterization
revealed no significant epicardial coronary artery disease,
the patient was taking long-acting oral nitrates and calcium
antagonists for recurrent nonexertional chest pain and a pre-
sumed diagnosis of variant angina. At the time of the opera-
tion, inspection of the mitral valve revealed myxomatous
characteristics with a redundant posterior leaflet, an associ-
ated posterior leaflet cleft, and override of the anterior leaflet.
Repair was performed by using primary suture closure of the
cleft, followed by annuloplasty with a 30-mm Cosgrove–
Edwards device (Edwards Lifesciences, Irvine, Calif). A
postrepair transesophageal echocardiogram revealed trivial
residual mitral valve regurgitation and preserved biventricu-
lar function, without significant transmitral or subaortic gra-
dients.
The patient was off all vasoactive medications (which in-
cluded norepinephrine) within 3 hours of her operation and
was extubated uneventfully that afternoon. Shortly after me-
diastinal tube removal the following day (28 hours postoper-
atively), she experienced chest pain and a precipitous
decrease in her systolic blood pressure to 60 mm Hg. Her
cardiac index decreased to 0.7 L min1 m2, and her central
venous pressure of 23 mm Hg was identical to her diastolic
pulmonary artery pressure.Surface echocardiographic analysis during preparations
to reopen her chest for suspected tamponade revealed severe
global hypokinesis of both ventricles, with a left ventricular
ejection fraction of less than 10%. The patient’s mitral valve
repair appeared to be intact. Mediastinal exploration re-
vealed no evidence of bleeding, tamponade, or other surgical
complications. She was taken on an emergency basis to the
hybrid operating room–catheterization laboratory for further
evaluation and treatment. The diagnoses of left circumflex
coronary artery injury or coronary thrombus were enter-
tained. The patient was supported with intravenous infusions
of epinephrine, dopamine, and norepinephrine en route to
the hybrid operating room.
Open-chest intraoperative coronary angiographic analysis
was initiated, but engagement of the left coronary artery re-
sulted in pressure dampening and a sudden decrease in blood
pressure. After placement of a femoral intra-aortic balloon
pump (IABP), coronary angiographic analysis revealed dif-
fuse severe stenosis of the left anterior descending and right
coronary arteries, which is consistent with coronary vaso-
spasm (Figure 1). With intracoronary nitroglycerin infusion
into both the left and right coronary systems and a reduction
in the patient’s adrenergic medications, the patient’s vaso-
spasm improved but did not completely resolve. Infusions
of milrinone and nitroglycerin were initiated, the patient’s
norepinephrine was weaned to 5 mg/min, and her chest
was closed.
Over the next week, the patient demonstrated steady he-
modynamic improvement. Repeated echocardiograms dem-
onstrated normalization of biventricular function, and her
IABP was removed 4 days after her reoperation. The patient
was restarted on a long-acting oral nitrate and calcium an-
tagonist. She was discharged home 20 days after her origi-
nal operation and has been free of dyspnea and angina to
date.
DISCUSSION
Although it is likely underrecognized, clinically signifi-
cant coronary vasospasm has been reported to occur afterrdiovascular Surgery c Volume 140, Number 2 e25
